3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Completed
4
Recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gynecologic
1
Conditions
Pancreatic Neoplasms
54
Biliary Tract Neoplasms
23
Nasopharyngeal Carcinoma
22
Carcinoma, Non-Small-Cell Lung
22
Cholangiocarcinoma
21
Urinary Bladder Neoplasms
18
Breast Neoplasms
18
Neoplasm Metastasis
17
Lung Neoplasms
14
Lymphoma, Large B-Cell, Diffuse
13
Colorectal Neoplasms
12
Carcinoma, Transitional Cell
12
Non-Muscle Invasive Bladder Neoplasms
10
Recurrence
8
Ovarian Neoplasms
8
Triple Negative Breast Neoplasms
7
Sarcoma
7
Neoplasms
6
Hodgkin Disease
6
Gallbladder Neoplasms
6
Nasopharyngeal Neoplasms
5
Bile Duct Neoplasms
5
Adenocarcinoma
5
Uterine Cervical Neoplasms
4
Locally Advanced Pancreatic Cancer
4
Endometrial Neoplasms
4
Parkinson Disease 4, Autosomal Dominant Lewy Body
3
Pancreatic Adenocarcinoma
3
Osteosarcoma
3
Lymphoma
3
Interventions
Oxaliplatin
5
Mitomycin
4
Hyperthermic Intraperitoneal Chemotherapy
4
Fluorouracil
4
Cisplatin
4
Doxorubicin
3
Standard of Care
2
Paclitaxel
2
Leucovorin
2
Docetaxel
2
Blood Specimen Collection
2
Bevacizumab
2
sodium thiosulfate
1
relacorilant
1
liposomal doxorubicin
1
irinotecan sucrosofate
1
dehydroftorafur
1
X-Rays
1
Topotecan
1
Specimen Handling
1
Practice Guidelines as Topic
1
Platinum
1
Pancreatectomy
1
Pafolacianine
1
Observation
1
Mitozytrex
1
Magnetic Resonance Spectroscopy
1
Letrozole
1
Laparoscopy
1
LY-2157299
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Recruiting
×
Peritoneal Neoplasms
×
Gemcitabine
×
Clear all
NCT07213804
2026-05-27
FRAmework-01
Eli Lilly and Company
Phase 3
Recruiting
1,080 enrolled